Non-Opioid Pain Management Solutions in Ann Arbor, MI

What I’d check before adding non opioid pain management here

Ann Arbor is a city under 250k (123,851 Census). CDC PLACES (2023, crude) estimates 6.4% of adults in Ann Arbor have diagnosed diabetes — 5.6 points below the U.S. 12% figure. Adult arthritis here is 16.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.

Epidemiology is not a protocol

• Adult arthritis here is 16.7% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 6% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Michigan.
• In a city under 250k, vendor noise is the operational problem: too many look-alike allograft flyers, too little chain-of-custody paperwork. Hawk Medical ships nationwide with HCT/P documentation; we do not invent a Ann Arbor street address.
• Medicare wound-care biologics in Michigan are paid under WPS Government Health Administrators (J8). CTP and skin-substitute LCDs are MAC-specific — a protocol that billed cleanly in another jurisdiction can stall here if documentation does not match J8 coverage articles.

What CDC PLACES and J8 each actually tell you

J8 reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Ann Arbor is 6.4% or not. PLACES is planning data. The LCD is the claim.

Before the first non opioid pain management shipment